Concepedia

Evelyn Wang

EW

Statistics

Publications

2

Citations

106

H-Index

2

Active since

2013

Affiliations

BioMarin (United States)(Current)

Newcastle University

Evelyn Wang is an author at BioMarin (United States) specializing in oncology, molecular oncology, and cancer pharmacology.

Publications per year

2013–2015

2

Publications

2

First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors.

Johann S. de Bono, Lida A. Mina, Michael Gonzalez et al. · Journal of Clinical Oncology · 2013 · 76 citations

Medicine, Oncology, Pharmacology +13

PARP1 expression, activity and<i>ex vivo</i>sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia

Ashleigh Herriott, Susan J. Tudhope, G.C.A. Junge et al. · Oncotarget · 2015 · 30 citations · Full text

Medicine, Oncology, Pharmacology +15

1–2 of 2